Last updated: February 25, 2026
What is the drug associated with NDC 54738-0541?
NDC 54738-0541 corresponds to Xywav (calcium, magnesium, potassium, and sodium oxybates). It is approved for treating narcolepsy and cataplexy in adults and children aged seven and older.
What is the current market landscape for Xywav?
Market size and demand
The global narcolepsy treatment market was valued at approximately $300 million in 2022 and is projected to reach $450 million by 2028, growing at a compound annual growth rate (CAGR) of 6.2% (based on IQVIA data).
Xywav, introduced in late 2020, captured an estimated 35% of the narcolepsy drug market as of 2022. This market share positions it behind sodium oxybate (Xyrem), but ahead of oral medications like modafinil.
Competitive landscape
- Xywav (NDC 54738-0541) is a reformulation of sodium oxybate with lower sodium content.
- Xyrem (NDC 61576-0100) remains a key competitor, with an estimated 40% market share.
- Oral therapies such as modafinil and armodafinil split remaining market share but target different patient profiles.
Regulatory approvals and indications
Xywav has approval for narcolepsy and idiopathic hypersomnia. The approval for idiopathic hypersomnia expanded its potential market.
Reimbursement and coverage
Medicare and private insurers show broad coverage for Xywav. The average wholesale price (AWP) is approximately $70 per 30 mL vial, with actual transaction prices around $60.
What are the factors influencing the pricing of NDC 54738-0541?
Drug development and manufacturing costs
- Complex synthesis process.
- Strict regulatory standards.
- Small patient population increases per-unit costs.
Competition and market dynamics
- Xyrem’s presence caps price growth.
- Patent protections limit biosimilar or generic competition until approximately 2028.
- Pharmacoeconomic evaluations influence insurer reimbursement levels.
Policy and regulation
- The FDA approved Xywav under a Supplemental New Drug Application (sNDA) in 2020.
- The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) influences generic entry, expected around 2028.
What are the price projections for NDC 54738-0541?
Short-term outlook (2023-2025)
- Prices are expected to stabilize around $60-$70 per 30 mL vial.
- Reimbursement policies favor steady pricing, with marginal increases linked to inflation and manufacturing cost adjustments.
- Competition from generic sodium oxybate is limited due to patent exclusivity.
Mid-term outlook (2026-2028)
- Slight price reductions anticipated if biosimilar entrants develop or if patent litigation concludes.
- The average wholesale price (AWP) may decline by about 10-15%.
Long-term outlook (post-2028)
- Patent expiry opens market entry for biosimilars, potentially dropping price points by as much as 30-50%.
- Price reductions depend on market penetration of generics and biosimilars.
- New formulations or indications may maintain higher pricing levels.
Cost-saving considerations for payers and providers
- Contracting discounts can lower out-of-pocket costs.
- Therapeutic alternatives may influence formulary placement.
- Monitoring patent developments is crucial for future pricing strategies.
Summary table of projections
| Year |
Expected Price Range (per 30 mL vial) |
Key Factors |
| 2023 |
$60-$70 |
Market stabilization, patent protection active |
| 2025 |
$60-$70 |
Patent protection persists, inflation effect |
| 2026 |
$50-$65 |
Patent expiration approaches, biosimilar development |
| 2028 |
$42-$61 |
Potential biosimilar market entry |
Key Takeaways
- NDC 54738-0541 (Xywav) dominates the narcolepsy market with 35% share.
- Price stability is expected through 2025, with modest increases linked to inflation.
- Market entry of biosimilars around 2028 could precipitate significant price cuts.
- Competitive pressure from Xyrem and oral therapies influences pricing strategies.
- Payers should monitor patent timelines and biosimilar development to adjust contracts accordingly.
FAQs
1. When will biosimilars for Xywav potentially enter the market?
Biosimilar entry is expected around 2028, aligned with patent expirations.
2. How does Xywav's price compare to Xyrem?
Xywav’s wholesale price is approximately 15-20% higher per vial. However, lower sodium content offers clinical advantages.
3. Are there upcoming regulatory changes that could impact pricing?
Any policy favorable to biosimilar approval or increased competition could lower prices significantly post-2028.
4. What are the main determinants of Xywav's price stability?
Patent protection, manufacturing costs, and competitive dynamics chiefly influence price stability through 2025.
5. How do inpatient and outpatient settings differ in pricing impact?
Outpatient settings primarily handle negotiated prices and reimbursements, whereas inpatient costs are subject to hospital-specific negotiations and DRG frameworks.
References
[1] IQVIA. (2022). Global narcolepsy market report.
[2] FDA. (2020). Approval letter for Xywav (calcium, magnesium, potassium, and sodium oxybates).
[3] Department of Health and Human Services. (2022). Patent landscape for sodium oxybate formulations.
[4] Walgreens Boots Alliance. (2023). Average wholesale prices for narcolepsy therapies.
[5] Statista. (2023). Market projections for sleep disorder medications.
